Humacyte
HUMA
141 hedge funds and large institutions have $79.8M invested in Humacyte in 2025 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 39 increasing their positions, 46 reducing their positions, and 29 closing their positions.
7.84% less ownership
Funds ownership: 36.69% → 28.85% (-7.8%)
10% less funds holding
Funds holding: 156 → 141 (-15)
15% less repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 46
22% less call options, than puts
Call options by funds: $1M | Put options by funds: $1.28M
33% less capital invested
Capital invested by funds: $119M → $79.8M (-$39.1M)
45% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$1.41M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.02M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$784K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$525K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$289K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CP
CenterBook Partners
Greenwich,
Connecticut
|
-$6.16M |
| 2 |
State Street
Boston,
Massachusetts
|
-$3.89M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$3.57M |
| 4 |
Millennium Management
New York
|
-$2.75M |
| 5 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$1.37M |
HUMA Hedge Fund Activity: Q3 2025 in Review
141 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Humacyte (HUMA) for Q3 2025, worth a combined $79.8M — down 33% from $119M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of HUMA and 16 opened new positions — a net loss of 13 holders — while 46 trimmed existing stakes and 39 added.
The largest buyer was Morgan Stanley, adding an estimated $1.41M. The largest seller was CenterBook Partners, cutting an estimated $6.16M.
- 141 institutional investors held Humacyte (HUMA) as of Q3 2025, down from 156 in Q2 2025.
- Funds reported $79.8M of Humacyte stock for Q3 2025, down 33% quarter-over-quarter.
- 16 funds opened new Humacyte positions in Q3 2025 and 29 closed out, a net change of -13 holders.
- The largest Humacyte buyer in Q3 2025 was Morgan Stanley, an estimated $1.41M added.
- The largest Humacyte seller in Q3 2025 was CenterBook Partners, an estimated $6.16M sold.
Based on aggregated 13F filings for Q3 2025.